Working… Menu
Trial record 18 of 116 for:    Atenolol

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00669279
Recruitment Status : Completed
First Posted : April 30, 2008
Results First Posted : March 23, 2012
Last Update Posted : October 5, 2017
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful effects of high blood pressure on the body's organs. In the past, blood pressure has only been measured in the arms. However, blood pressure in the arms may not accurately reflect the blood pressure in the aorta and thus may mislead doctors treating high blood pressure. For this reason, we are testing whether two different medications for blood pressure, both in a class called beta blockers, have similar effects on blood pressure in the arm and aorta.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Carvedilol CR Drug: Atenolol Phase 4

Detailed Description:
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study) is a prospective, open-label, comparative, randomized control trial that evaluated brachial and central hemodynamic profiles in patients taking atenolol or controlled-release carvedilol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Non-Invasive Determination of Central Aortic Blood Pressure in Hypertensive Patients Treated With Controlled-Release Carvedilol or Atenolol
Study Start Date : April 2008
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Carvedilol CR Drug: Carvedilol CR
Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
Other Name: Coreg CR

Experimental: Atenolol Drug: Atenolol
Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
Other Name: Tenormin

Primary Outcome Measures :
  1. Central Aortic Blood Pressure [ Time Frame: Measured at baseline and 4 weeks. ]

Secondary Outcome Measures :
  1. Peripheral Blood Pressure [ Time Frame: Measured at baseline, 2 weeks, and 4 weeks. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age
  • Hypertension (untreated or treated with no more then one anti-hypertensive drug)

Exclusion Criteria:

  • Secondary forms of hypertension (including sleep apnea)
  • Patients currently treated with two or more antihypertensive drugs
  • Patients taking antihypertensive drugs with properly measured clinic systolic blood pressure greater then 170mmHg
  • Isolated systolic hypertension
  • Other diseases requiring treatment with blood pressure lowering medications
  • Heart rate less then 55 beats/min (in the absence of beta-blocker therapy)
  • Known cardiovascular disease including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and TIA)
  • Known diabetes mellitus (Type 1 or 2)
  • Renal insufficiency defined as a serum creatinine greater then 1.5mg/dL in males and 1.4mg/dL in females
  • Primary renal disease
  • Pregnancy or lactation
  • History of Raynaud's syndrome
  • Alcoholism and recreational drug use (due to compliance concerns)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00669279

Layout table for location information
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
Layout table for investigator information
Principal Investigator: Benjamin Epstein, Pharm.D. University of Florida

Layout table for additonal information
Responsible Party: University of Florida Identifier: NCT00669279     History of Changes
Other Study ID Numbers: 8COG11059
First Posted: April 30, 2008    Key Record Dates
Results First Posted: March 23, 2012
Last Update Posted: October 5, 2017
Last Verified: September 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Protective Agents
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Anti-Arrhythmia Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists